Drug Interactions between eliglustat and teclistamab

MONITOR: Coadministration with teclistamab may increase the plasma concentrations of drugs that are substrates of CYP450 isoenzymes. Initiation of teclistamab treatment causes transient release of cytokines that may suppress CYP450 isoenzymes, although the potential for interaction has not been studied. According to the manufacturer, the highest drug-drug interaction risk would be from the start of teclistamab therapy (including the initial step-up dosing schedule) up to 7 days after the first treatment dose (considered to be the first weekly dose administered after the completion of the step-up dosing schedule), as well as during and after cytokine release syndrome.

MANAGEMENT: Caution is advised when teclistamab is coadministered with drugs that are metabolized by CYP450 isoenzymes, particularly those with a narrow therapeutic range, where minimal changes to concentration may lead to significant adverse reactions, such as carbamazepine, colchicine, cyclosporine, disopyramide, phenytoin, quinidine, theophylline, warfarin, macrolide immunosuppressants, vinca alkaloids, and some narcotic analgesics. Clinical and/or laboratory monitoring are recommended, particularly at the initial phase of treatment with teclistamab as well as during and after cytokine release syndrome, and the dosage(s) of the CYP450 substrate(s) adjusted accordingly.